Clinical Report: Extending Peptide Release in Tissue Regeneration
Overview
This study investigates the use of electrostatic interactions to enhance the sustained release of osteogenic peptides from gelatin microparticles. Findings indicate that positively charged peptides can achieve controlled release for 14 to 21 days, influenced by the charge of both the peptide and the gelatin carrier.
Background
The ability to control peptide release is crucial in tissue regeneration and drug delivery applications. Sustained release systems can improve therapeutic efficacy. Understanding the interactions between peptides and delivery carriers can lead to more effective regenerative therapies.
Data Highlights
| Parameter | Findings |
|---|---|
| Release Duration | 14 to 21 days for positively charged peptides |
| Loading Efficiency | Greatest with positively charged peptide variants |
| Initial Burst Release | Reduced with positive charge modification |
| Swelling and Degradation | Minimal influence from conjugating peptide charge |
Key Findings
- Electrostatic interactions can extend peptide release from hydrogel systems.
- Positive charge modification of peptides allows for controlled release over 14 to 21 days.
- Peptide loading and release kinetics are influenced by the charge of both the peptide and the gelatin carrier.
- Increasing charged residues beyond four reduces peptide loading and increases burst release.
- Confocal microscopy shows peptide distribution throughout gelatin microparticles during release.
Clinical Implications
The findings suggest that manipulating electrostatic interactions can optimize peptide delivery systems.
Conclusion
The study demonstrates that electrostatic interactions can be a viable strategy for extending peptide release.
Related Resources & Content
- Jiang EY, et al., Cell Biomaterials, 2023 -- Extending Peptide Release in Tissue Regeneration
- MDSpire News — Can Peptides Improve Skin Aging?
- the medicine maker — The Cautious Comeback of Oral Peptides
- BJS (British Journal of Surgery) — 19 Antimicrobial Peptide-Enhanced Gelatin-Modified Hyaluronic Acid Hydrogels for the Management of Chronic Wounds
- Clinical Pharmacology Considerations for Peptide Drug Products | FDA
- Framework for the Regulation of Regenerative Medicine Products | FDA
- CMM-612: Grafts Guidelines
- Biologics Knowledge Base | American Academy of Orthopaedic Surgeons
- Clinical efficacy and safety of P-15 peptide enhanced bone graft substitute in surgical bone regenerative procedures in adult maxillofacial, spine, and trauma patients: a systematic literature review - PMC
- P-15 Peptide Enhanced Bone Graft in Transforaminal Lumbar Interbody Fusion: A Randomized, Controlled, Investigational Device Exemption Study Demonstrating Improved Composite Clinical Success - PMC
- ABM/P-15 Versus Allograft in Non-Instrumented Lumbar Fusion: Ten-Year Follow-Up of a Double Blind Randomized Controlled Trial - PMC
- Clinical Outcomes of Anorganic Bone Matrix Combined With a P-15 Osteogenic Cell-Binding Peptide (ABM/P-15) in One- and Two-Level Transforaminal Lumbar Interbody Fusion (TLIF): A Propensity-Matched Comparison - PubMed
- Bone morphogenetic protein, platelet-rich plasma, and bone marrow aspiration concentrate in the treatment of bone delayed union or nonunion: a systematic review and network meta-analysis of randomized controlled trials - PubMed
- Frontiers | Clinical trial landscape for guided bone regeneration: trend analysis and future perspectives
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
